AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02362906
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
Trial: NCT01357356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04049552
Drug: Rapamycin 8% Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A compounded ointment containing 8% rapamycin
Trial: NCT04049552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Petrolatum ointment placebo
Trial: NCT00548353
Drug: MK3207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
Trial: NCT00548353
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
Trial: NCT02056730
Drug: calcium sensing receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
Trial: NCT02297906
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drug
Trial: NCT01856192
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01856192
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03984448
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03984448
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00244517
Drug: TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
Trial: NCT00851344
Drug: GSK835726 (10mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK835726 (10mg) tablet
Trial: NCT00851344
Drug: GSK835726 (50mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK835726 (50mg) tablet
Trial: NCT00851344
Drug: GSK835726 (100mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK835726 (100mg) tablet
Trial: NCT04069078
Drug: Hyoscine Butylbromide 20 Mg/mL Solution for Injection Ampoule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive IV study solution which is hyoscine butylbromide 20 mg in 1 ml one minute after spinal anaesthesia
Trial: NCT03709680
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1 only: Administered at 250 mg/m2 (intravenous), on days 1-5 of a 21-day cycle
Trial: NCT02477969
Drug: PEX168(100µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
Trial: NCT02477969
Drug: PEX168(200µg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEX168,Subcutaneous injection,once a week. continued for 52 weeks
Trial: NCT02477969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
Trial: NCT01631812
Drug: SPM 962
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPM 962 transdermal patch once a daily up to 36.0 mg/day
Trial: NCT02482207
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01907100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib matching placebo
Trial: NCT02800902
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prophylaxis followed by placement of placebo gel
Trial: NCT02800902
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral prophylaxis followed by placement of rosuvastatin gel
Trial: NCT04407052
Drug: Double trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final follicular maturation is triggered by the coadministration of GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom) and 10000 IU of HCG, 40 and 34 h prior to oocyte retrieval, respectively
Trial: NCT04407052
Drug: HCG trigger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Final follicular maturation is triggered by a dose of 10000 IU of HCG 36 h prior to oocyte retrieval
Trial: NCT03655210
Drug: HL151
RxNorm normalized name: Hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL151(1Tab) once a day for 4 weeks of treatments
Trial: NCT00805701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03954132
Drug: Spiolto® Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to Spiolto® Respimat® inhaler by their attending physician in an real-world setting.
Trial: NCT03954132
Drug: Triple-Therapy (LAMA/LABA/ICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic Obstructive Pulmonary Disease (COPD) patients who were symptomatic (dyspneic) despite Long-acting beta2 adrenoceptor agonist/Inhalative Corticosteroids (LABA/ICS) maintenance treatment were switched to any triple therapy Long-acting muscarinic antagonist + Long-acting beta2 adrenoceptor agonist + Inhalative Corticosteroids (LAMA + LABA + ICS) by their attending physician in an real-world setting.
Trial: NCT00376428
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00979628
Drug: sliding scale regular insulin (SSRI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four-time daily in patients with T2DM admitted to general medicine and surgery wards.
Trial: NCT00979628
Drug: Basal Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
Trial: NCT00979628
Drug: Basal Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
Trial: NCT00309478
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600mg/m2
Trial: NCT00309478
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 40mg/m2
Trial: NCT00309478
Drug: Fluorouracil implant
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil 600mg/m2
Trial: NCT02479828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03318900
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02764697
Drug: H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection twice weekly
Trial: NCT03104374
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT03104374
Drug: ABT-494
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06680505
Drug: YZJ-1139 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YZJ-1139 10mg tablets
Trial: NCT06680505
Drug: YZJ-1139 20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YZJ-1139 20mg tablets
Trial: NCT06680505
Drug: YZJ-1139 40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YZJ-1139 40mg tablets
Trial: NCT06680505
Drug: YZJ-1139 60mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YZJ-1139 60mg tablets
Trial: NCT06680505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Match placebo tablets
Trial: NCT01211847
Drug: Diazoxide Choline Controlled-Release Tablet
RxNorm normalized name: diazoxide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCCR 290 mg once a day for 126 days
Trial: NCT02883192
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01397201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching fluticasone propionate HFA MDI
Trial: NCT02905253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching AC-084 capsules
Trial: NCT02294084
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a placebo (once a day) for 12 weeks.
Trial: NCT03623451
Drug: Chinese Medicine Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Medicine Formula, composed of American ginseng 10g, Poria cocos 15g, bighead atractylodes rhizome 20g, Astragalus mongholicus 30g, Crataegus pinnatifida Bunge 20g, Salvia miltiorrhiza Bge. 20g, Pericarpium Citri Reticulatae 10g will be decocted and packaged into vacuum packs by the pharmaceutical department of First Affiliated Hospital, Heilongjiang University of Chinese Medicine (140 mL/pack). Subjects will take 2 packages per day for three months.
Trial: NCT01211847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching DCCR
Trial: NCT01964131
Drug: D961H HPMC capsule 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will be randomised evenly to one of Treatment: A--\>B (Sequence 1) or Treatment: B--\>A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg
Trial: NCT03280537
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Trial: NCT00003782
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
Trial: NCT02739165
Drug: ART-123
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
Trial: NCT02739165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by intravenous drip infusion in addition to standard of care steroid therapy
Trial: NCT00003782
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
Trial: NCT02002247
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
Trial: NCT02528175
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 weeks concurrent with radiation therapy (institutional standard).
Trial: NCT04467931
Drug: ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterans will be categorized as exposed to ACEI/ARB if they have one or more pharmacy fills for an oral ACEI or an ARB in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
Trial: NCT03705585
Drug: Vivotif Typhoid Oral Vaccine
RxNorm normalized name: Vivotif Typhoid Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Trial: NCT04467931
Drug: Non-ACEI/ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterans will be categorized as exposed to a non-ACEI/ARB if they have one or more pharmacy fills for an oral non-ACEI or ARB medication in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an ACEI/ARB medication in the 90 days (± 14 days) prior to each Veteran's index date. Specific drug classes include: aldosterone receptor antagonist, beta-blocker, calcium channel blocker, centrally-acting drug, direct arterial vasodilator, direct renin inhibitor, thiazide diuretic, loop diuretic, and potassium sparing diuretic.
Trial: NCT04467931
Drug: ACEI
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterans will be categorized as exposed to an ACEI if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ARB in the 90 days (± 14 days) prior to each Veteran's index date.
Trial: NCT04467931
Drug: ARB
RxNorm normalized name: Arbli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veterans will be categorized as exposed to an ARB if they have one or more pharmacy fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date and NO fills for an oral ACEI in the 90 days (± 14 days) prior to each Veteran's index date. Sacubitril/valsartan (Brand name: Entresto®) will be excluded from ARB exposures.
Trial: NCT00408538
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01238185
Drug: acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01340547
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
Trial: NCT00646906
Drug: Acetaminophen 1000 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a daily oral dose of 1000 mg acetaminophen for six days each administered at 8 AM.
Trial: NCT00646906
Drug: Ibuprofen 800 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover period Ibuprofen 800 mg/d: Ibuprofen (200 mg) orally at at 8 AM, 2 PM, 8 PM and 2 AM for 3 days. The last dose will be administered on day four at 8 AM.
Trial: NCT00401739
Drug: CSL360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly IV Infusion. Dose escalation study.
Trial: NCT02931136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will treatment by the placebo in 52 weeks.
Trial: NCT03302195
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Based on patient body weight (UI/kg)
Trial: NCT02840240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
Trial: NCT01348607
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02126358
Drug: Gemigliptin and/or Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01240876
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo vials will be filled with the buffered solution for CEP-37247.
Trial: NCT03141073
Drug: HMS5552
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID oral administration
Trial: NCT03141073
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BID oral administration
Trial: NCT01737450
Drug: BKM120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03090412
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo PDT
Trial: NCT04603937
Drug: KSI-301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection
Trial: NCT04104334
Drug: Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume
Trial: NCT04104334
Drug: Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100, according to anesthesia usual practices
Trial: NCT03115073
Drug: Candiplus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Candiplus
Trial: NCT04541888
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00928252
Drug: IV fluorine-18 labeled methylcholine before PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention at pre-treatment, and at two timepoints post treatment intiation.
Trial: NCT01385631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
Trial: NCT00057954
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of Methotrexate is based on the corrected ideal body weight for patients with \> 33% above ideal weight.~Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)
Trial: NCT00315146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00630643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00808678
Drug: ABT-143
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once, see arm description for more information
Trial: NCT00808678
Drug: ABT-335
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once, see arm description for more information
Trial: NCT00808678
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once, see arm description for more detail
Trial: NCT03630211
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Stem Cell Mobilization
Trial: NCT03098836
Drug: ARN-509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg orally daily
Trial: NCT00082589
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03887533
Drug: VTS-270
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous VTS-270 was administered on a monthly dosing schedule for 12 months. Each participant received one of two doses (500 or 1000mg/kg). Participants also received monthly 900 mg intrathecal VTS-270 therapy.
Trial: NCT00002665
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
Trial: NCT00530400
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preoperative intravenous placebo
Trial: NCT00002665
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: main: 25 mg/m2 IV 1, 8, 15, and 22
Trial: NCT00002665
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC \< 3,000 /μl
Trial: NCT00002665
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: con: 60 mg/m2 PO 1 - 28